THE IBSA group
A turning point in IBSA’s history was in 1985, when the current management took over the company, fully redefining its vision and strategy, placing IBSA on the international scene for the first time. After taking its first steps on the domestic market, IBSA embarked upon an exceptional and intensive development program with the aim of expanding company assets and creating a competitive portfolio of products covering 9 main therapeutic areas, which have resulted in IBSA holding a leading position in the world markets.
Pain & Inflammation
Endocrinology
Cardiometabolic
Urology
Osteoarticular
Dermoaesthetic
Dermatology
Human Reproduction
Respiratory
Thanks to its consolidated expansion strategy, IBSA products are currently marketed in 5 continents and in more than 80 countries worldwide, including China and the United States.
As a result of this extensive expansion, the Group employs a total of 2000 people, distributed among the various offices and production sites, and has 13 branches in Europe, China and the United States, as well as 14 Research and Development laboratories worldwide.
Today IBSA is the largest privately-owned pharmaceutical company in Switzerland.
IBSA Technology
IBSA aims to be a benchmark for the manufacture of pharmaceutical products and innovative administration systems with proven efficacy that significantly improve the quality of the molecules and therapeutic solutions already on the market. In order to do so, it develops special technologies
Soft-gel technology enables a liquid or gel matrix to be incorporated into a soft gelatin capsule, making the administration of drugs easier and improving the compliance of the patient
IBSA has the technological know-how to develop and manufacture transdermic and topical patches based on both hydrogel and drug-in-adhesive technology in its own manufacturing plants. This know-how renders IBSA unique in the European pharmaceutical landscape, as it is one of the few companies in the world that can offer both of these prevailing technologies
The use of polymeric films for the oral administration of drugs has developed great potential in recent years. Once placed on the tongue, the orally disintegrating film (ODF) is hydrated immediately with saliva, disintegrating and/or dissolving and releasing an active pharmaceutical agent
IBSA has developed a unique and innovative production technology known as NAHYCO® Hybrid Technology, which creates a new method of intervention for thermally-stabilizing hyaluronic acid with high molecular weight (H-HA) and hyaluronic acid with low molecular weight (L-HA) or with other glycosaminoglycans (i.e. sodium chondroitin). This technology not only increases the life of the hyaluronic acid, but also guarantees its maximum concentration without compromising its manageability and safety
One of the “core” manufacturing capabilities of IBSA is the production of prefilled syringes, ready-to-use. This offers the undoubted advantage of preserving the final product in sterile conditions, avoiding the manipulation and preparation from the traditional ampoules and facilitating the administration by the physician
Osteoarticular & pain areas
IBSA’s portfolio for osteoarticular/musculoskeletal diseases and for pain management offers different therapeutic options both for the physician and the patient with acute (i.e. sport traumas) and chronic conditions (i.e. osteoarthritis/OA). For more information please visit the IBSA website: https://www.ibsagroup.com/
Partners in Academy
Mast&r Educational aims to create an innovative teaching methodology where science, technology and know-how are integrated to enhance theoretical and practical skills, with special focus on the anatomy and pathophysiology of the musculoskeletal system.
We can sum up our method in one sentence: “Watch to remember, practise to learn, practise to understand”.
Use of teaching tools where “seeing” amplifies the capacity to memorize and understand information, and to create courses where “doing” allows the practice and mastering of useful procedures for day-to-day medical work. Mast&r Educational has created two projects dedicated to medical safety which are applicable to every healthcare professional: “Safe Medical Procedure project-SMP” and the “Safe Surgery Procedure project-SSP”.
The SMP & SSP Projects teach, via the ultrasound lab, PC lab, wet & dry labs and the cadaver lab, the execution of procedures in total safety thanks to our study, analysis and understanding of all the risk factors.
The IBSA International Academy – Musculoskeletal Modules sums up our vision, goals, and educational philosophy.
HPS – Health Publishing and Services is a leading Italian healthcare publishing and consultancy firm and is the publisher of several media products including:
AboutPharma, a monthly magazine read by national and regional institutions, health authorities, NHS managers, clinicians, pharmacists universities and research centers, pharma and medical devices managers, scientific societies, managers and professionals of healthcare-related services
AboutPharma Online, the daily newspaper for the healthcare professional, focused on healthcare topics including regional and national health policies, medicine and research, health economics, life science companies, legal and regulatory
AboutPharma Animal Health, launched in 2019, a quarterly magazine covering health policies, market trends, business strategies relevant to Animal Health and its tight relationship, as stated by the WHO, with human health
HPS develops workshops, seminars and training events under the brand AboutAcademy.
Since 2013, HPS organizes the AboutPharma Digital Awards, the most important award in Italy specifically focussed on digital health.
Lastly, HPS creates tools, products and services in the biomedical, HTA and market access space tailored to lifescience industries.
